Last reviewed · How we verify
Arm 2 - Magnevist
Magnevist, marketed by Bracco Diagnostics, Inc., is a well-established contrast agent in the diagnostic imaging market. The drug's key composition patent is set to expire in 2028, providing a significant period of market exclusivity. However, the lack of reported revenue and primary trial results poses a risk in assessing its ongoing market performance and competitive edge.
At a glance
| Generic name | Arm 2 - Magnevist |
|---|---|
| Also known as | gadopentetate dimeglumine |
| Sponsor | Bracco Diagnostics, Inc |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years (PHASE4)
- Programmed Ventricular Stimulation to Risk Stratify for Early Cardioverter-Defibrillator (ICD) Implantation to Prevent Tachyarrhythmias Following Acute Myocardial Infarction (PROTECT-ICD) (NA)
- P03277 Dose Finding Study in Central Nervous System (CNS) Magnetic Resonance Imaging (MRI) (PHASE2)
- Multihance at 3 Tesla (3T) in Brain Tumors (PHASE4)
- Contrast- Enhanced Whole-Heart Coronary MRA at 3.0T (Tesla) (PHASE1)
- Crossover Comparison of MultiHance and Dotarem (PHASE4)
- Magnevist® Injection Enhanced MRA Compared to Non Contrast MRA for the Detection of Stenosis in the Calf and/or Pedal Arteries (PHASE3)
- Gadobutrol Magnevist-controlled Body Study (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Arm 2 - Magnevist CI brief — competitive landscape report
- Arm 2 - Magnevist updates RSS · CI watch RSS
- Bracco Diagnostics, Inc portfolio CI